174 related articles for article (PubMed ID: 34112113)
1. Tobacco use in the Myeloproliferative neoplasms: symptom burden, patient opinions, and care.
Christensen SF; Scherber RM; Mazza GL; Dueck AC; Brochmann N; Andersen CL; Hasselbalch HC; Mesa RA; Geyer HL
BMC Cancer; 2021 Jun; 21(1):691. PubMed ID: 34112113
[TBL] [Abstract][Full Text] [Related]
2. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs.
Emanuel RM; Dueck AC; Geyer HL; Kiladjian JJ; Slot S; Zweegman S; te Boekhorst PA; Commandeur S; Schouten HC; Sackmann F; Kerguelen Fuentes A; Hernández-Maraver D; Pahl HL; Griesshammer M; Stegelmann F; Doehner K; Lehmann T; Bonatz K; Reiter A; Boyer F; Etienne G; Ianotto JC; Ranta D; Roy L; Cahn JY; Harrison CN; Radia D; Muxi P; Maldonado N; Besses C; Cervantes F; Johansson PL; Barbui T; Barosi G; Vannucchi AM; Passamonti F; Andreasson B; Ferrari ML; Rambaldi A; Samuelsson J; Birgegard G; Tefferi A; Mesa RA
J Clin Oncol; 2012 Nov; 30(33):4098-103. PubMed ID: 23071245
[TBL] [Abstract][Full Text] [Related]
3. Item nonresponse on the Myeloproliferative Neoplasms Symptom Assessment Form (MPN-SAF): a comparison of missing data strategies.
Mazza GL; Kunze KL; Langlais BT; Kosiorek HE; DeWees TA; Geyer HL; Scherber RM; Mesa RA; Dueck AC
Leuk Lymphoma; 2019 Jul; 60(7):1789-1795. PubMed ID: 30652523
[TBL] [Abstract][Full Text] [Related]
4. The SIMM study: Survey of integrative medicine in myeloproliferative neoplasms.
Gowin K; Langlais BT; Kosiorek HE; Dueck A; Millstine D; Huberty J; Eckert R; Mesa RA
Cancer Med; 2020 Dec; 9(24):9445-9453. PubMed ID: 33140580
[TBL] [Abstract][Full Text] [Related]
5. Depressive symptoms and myeloproliferative neoplasms: Understanding the confounding factor in a complex condition.
Padrnos L; Scherber R; Geyer H; Langlais BT; Dueck AC; Kosiorek HE; Senyak Z; Clark M; Boxer M; Cotter M; Harrison C; Stonnington C; Geda Y; Mesa R
Cancer Med; 2020 Nov; 9(22):8301-8309. PubMed ID: 32976697
[TBL] [Abstract][Full Text] [Related]
6. Anxiety and depression in patients with Philadelphia-negative myeloproliferative neoplasms: a nationwide population-based survey in Denmark.
Brochmann N; Flachs EM; Christensen AI; Bak M; Andersen CL; Juel K; Hasselbalch HC; Zwisler AD; Rottmann N
Clin Epidemiol; 2019; 11():23-33. PubMed ID: 30588121
[TBL] [Abstract][Full Text] [Related]
7. Myeloproliferative neoplasm patient symptom burden and quality of life: evidence of significant impairment compared to controls.
Anderson LA; James G; Duncombe AS; Mesa R; Scherber R; Dueck AC; de Vocht F; Clarke M; McMullin MF
Am J Hematol; 2015 Oct; 90(10):864-70. PubMed ID: 26113113
[TBL] [Abstract][Full Text] [Related]
8. Tobacco Smoking and Psychotic-Like Experiences in a General Population Sample.
Mallet J; Mazer N; Dubertret C; Le Strat Y
J Clin Psychiatry; 2018 Oct; 79(6):. PubMed ID: 30289630
[TBL] [Abstract][Full Text] [Related]
9. Effect of tobacco smoking on outcomes after left ventricular assist device implantation.
Combs P; Imamura T; Siddiqi U; Spiller RE; Williamson R; Mirzai S; Symalla T; LaBuhn C; Jeevanandam V
Artif Organs; 2020 Jul; 44(7):693-699. PubMed ID: 32017136
[TBL] [Abstract][Full Text] [Related]
10. Tobacco smoking in patients with heart failure and coronary artery disease: A 20-year experience at Duke University Medical Center.
Grubb AF; Pumill CA; Greene SJ; Wu A; Chiswell K; Mentz RJ
Am Heart J; 2020 Dec; 230():25-34. PubMed ID: 32980363
[TBL] [Abstract][Full Text] [Related]
11. The role of sexuality symptoms in myeloproliferative neoplasm symptom burden and quality of life: An analysis by the MPN QOL International Study Group.
Geyer HL; Andreasson B; Kosiorek HE; Dueck AC; Scherber RM; Martin KA; Butler KA; Harrison CN; Radia DH; Cervantes F; Kiladjian JJ; Reiter A; Birgegard G; Passamonti F; Senyak Z; Vannucchi AM; Paoli C; Xiao Z; Samuelsson J; Mesa RA
Cancer; 2016 Jun; 122(12):1888-96. PubMed ID: 27070130
[TBL] [Abstract][Full Text] [Related]
12. [Analysis of the MPN Landmark survey for impact and perceptions of treatment goals among Chinese physicians and myeloproliferative neoplasm patients].
Xu ZF; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2020 Jul; 41(7):570-575. PubMed ID: 32810964
[No Abstract] [Full Text] [Related]
13. Association between quality of life and clinical parameters in patients with myeloproliferative neoplasms.
Johansson P; Mesa R; Scherber R; Abelsson J; Samuelsson J; Birgegård G; Andréasson B
Leuk Lymphoma; 2012 Mar; 53(3):441-4. PubMed ID: 21883029
[TBL] [Abstract][Full Text] [Related]
14. Patients with polycythemia vera have worst impairment of quality of life among patients with newly diagnosed myeloproliferative neoplasms.
Abelsson J; Andréasson B; Samuelsson J; Hultcrantz M; Ejerblad E; Johansson B; Emanuel R; Mesa R; Johansson P
Leuk Lymphoma; 2013 Oct; 54(10):2226-30. PubMed ID: 23398206
[TBL] [Abstract][Full Text] [Related]
15. Associations between smoking status and bodily pain in a cross-sectional survey of UK respondents.
Perski O; Garnett C; Shahab L; Brown J; West R
Addict Behav; 2020 Mar; 102():106229. PubMed ID: 31862683
[TBL] [Abstract][Full Text] [Related]
16. Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group.
Geyer HL; Kosiorek H; Dueck AC; Scherber R; Slot S; Zweegman S; Te Boekhorst PA; Senyak Z; Schouten HC; Sackmann F; Fuentes AK; Hernández-Maraver D; Pahl HL; Griesshammer M; Stegelmann F; Döhner K; Lehmann T; Bonatz K; Reiter A; Boyer F; Etienne G; Ianotto JC; Ranta D; Roy L; Cahn JY; Harrison CN; Radia D; Muxi P; Maldonado N; Besses C; Cervantes F; Johansson PL; Barbui T; Barosi G; Vannucchi AM; Paoli C; Passamonti F; Andreasson B; Ferrari ML; Rambaldi A; Samuelsson J; Cannon K; Birgegard G; Xiao Z; Xu Z; Zhang Y; Sun X; Xu J; Kiladjian JJ; Zhang P; Gale RP; Mesa RA
Haematologica; 2017 Jan; 102(1):85-93. PubMed ID: 27540137
[TBL] [Abstract][Full Text] [Related]
17. UK results from the myeloproliferative neoplasms (MPN) landmark survey on the symptom, emotional and economic burden of MPN.
Harrison C; Mathias J; Campbell-Drew M; Mead AJ; Pemberton-Whiteley Z; Ali S; Wadelin F; Taylor-Stokes G; Waller J; Taylor B
Br J Haematol; 2019 Aug; 186(3):e1-e4. PubMed ID: 30854625
[No Abstract] [Full Text] [Related]
18. Disabled, invisible and dismissed-The lived experience of fatigue in people with myeloproliferative neoplasms.
Bradford A; Young K; Whitechurch A; Burbury K; Pearson EJM
Cancer Rep (Hoboken); 2023 Jan; 6(1):e1655. PubMed ID: 35705529
[TBL] [Abstract][Full Text] [Related]
19. Quality of life and symptom burden among myeloproliferative neoplasm patients: do symptoms impact quality of life?
Langlais BT; Geyer H; Scherber R; Mesa RA; Dueck AC
Leuk Lymphoma; 2019 Feb; 60(2):402-408. PubMed ID: 30033837
[TBL] [Abstract][Full Text] [Related]
20. Comprehensively understanding fatigue in patients with myeloproliferative neoplasms.
Scherber RM; Kosiorek HE; Senyak Z; Dueck AC; Clark MM; Boxer MA; Geyer HL; McCallister A; Cotter M; Van Husen B; Harrison CN; Mesa RA
Cancer; 2016 Feb; 122(3):477-85. PubMed ID: 26670597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
